Sunho Biologics Reports Reduced Bi-Annual Loss

Sunho Biologics,Inc. (HK:2898) has released an update.

Sunho Biologics, Inc. has reported its unaudited interim financial results for the first half of 2024, highlighting a reduction in loss for the period to RMB 36,077 thousand compared to RMB 61,489 thousand in the same period last year. The Group’s financial health appears to be on the rise with a significant increase in cash and cash equivalents from RMB 125.1 million to RMB 493.9 million. Despite increased R&D and listing expenses, the overall financial loss has decreased, signaling a potential turnaround for the company.

For further insights into HK:2898 stock, check out TipRanks’ Stock Analysis page.